Heska Corporation

• 01.04.2020 – 15:47

  Heska Corporation vollzieht Übernahme von scil animal care; neuer Weltmarktführer in der veterinärmedizinischen Point-of-Care-Diagnostik

  Loveland, Colorado (ots/PRNewswire) - Unternehmen klettert auf Platz 1 und Platz 2 in Schlüsselmärkten und erweitert Reichweite auf 25 Länder Heska Corporation (NASDAQ: HSKA; "Heska" oder das "Unternehmen"), ein Anbieter von fortschrittlichen veterinärmedizinischen Diagnose- und Spezialprodukten, gab heute den ...

  mehr

• 04.02.2020 – 14:00

  Heska Corporation setzt Telefonkonferenz zu den Finanzergebnissen und Erträgen für das vierte Quartal und volle Geschäftsjahr 2019 für den 25. Februar 2020 an

  Loveland, Colorado (ots/PRNewswire) - Die Heska Corporation (NASDAQ: HSKA; "Heska" oder das "Unternehmen"), ein Anbieter von fortschrittlichen veterinärmedizinischen Diagnose- und Spezialprodukten, möchte ihre Finanzergebnisse des vierten Quartals und vollen Geschäftsjahres 2019 am 25. Februar in einer ...

  mehr

• 15.01.2020 – 12:38

  Heska Corporation übernimmt scil animal care, einen europäischen Marktführer in der veterinärmedizinischen Point-of-Care-Diagnostik

  Loveland, Colorado (ots/PRNewswire) - Unternehmen klettert auf Platz 1 und Platz 2 in Schlüsselmärkten und erweitert Reichweite auf 25 Länder Heska Corporation (NASDAQ: HSKA - News; "Heska" oder das "Unternehmen"), ein Anbieter von fortschrittlichen veterinärmedizinischen Diagnose- und Spezialprodukten, gab ...

  mehr

• 29.03.2001 – 13:50

  Heska announces new clinical chemistry analyser

  Fort Collins, USA (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced the introduction of its new SPOTCHEM EZ(TM) clinical biochemistry analyser. (Photo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) The SPOTCHEM EZ is a compact desktop system used to measure all common blood chemistry components and offers 19 different biochemical tests that are vital to veterinary medical ...

  mehr

• 19.03.2001 – 13:02

  Heska and Novartis enter into canadian distribution pact

  Fort Collins, Colorado (ots-PRNEwswire) - Heska Corporation (Nasdaq: HSKA), today announced that it has entered into a distribution agreement with Novartis Animal Health Canada, Inc., a subsidiary of Novartis AG of Basel, Switzerland, granting Novartis exclusive distribution rights for the sale of the HESKAô Flu Avertô I.N. vaccine in Canada. Financial terms of the agreement were not disclosed. (Photo: ...

  mehr

• 15.03.2001 – 13:02

  Patent granted for Heska Corporation's equine influenza vaccine

  Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced the recent issuance of a patent covering its equine influenza vaccine, Flu Avert(TM) I.N. vaccine. (Photo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) The vaccine, introduced by Heska in the United States in November 1999, has proven to be safe and ...

  mehr

• 07.03.2001 – 12:59

  Heska Corporation to market new diagnostic product developed by Genzyme Corporation

  Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced that it has obtained marketing rights to a new product for the detection of Giardia and Cryptosporidium from Genzyme Corporation. The agreement grants to Heska broad rights to market the product in the companion animal health market. Financial terms of the agreement were not ...

  mehr

• 20.02.2001 – 14:01

  Heska Corporation reports 2000 fourth quarter and year-end results / Company delivers record annual revenue, improved margins and reduced operating expenses

  Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), a research and development based biotechnology company focusing on companion animal health care products, today reported financial results for the fourth quarter and year ended December 31, 2000. Photo: ...

  mehr

• 07.02.2001 – 13:00

  Heska completes US$5.7 million private placement

  Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) announced today that it has completed a private placement of approximately 4.57 million shares of common stock for aggregate proceeds of approximately US$5.7 million with a group of institutional investors, including existing stockholders of Heska. Wells Fargo Van Kasper acted as a financial advisor with respect to the transaction. Heska intends ...

  mehr

• 02.02.2001 – 12:00

  Heska Corporation licences genes to Torrey Mesa Research Institute to test potential allergy treatments

  Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), a leader in the companion animal health market, today announced that it has entered into an exclusive agreement with the Torrey Mesa Research Institute ("TMRI") to evaluate a collection of Heska's proprietary genes in TMRI's novel ...

  mehr

• 23.01.2001 – 17:06

  Heska introduces new clinical chemistry analyser

  Fort Collins, Colorado (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced the introduction of its new Chem-Elite(TM) Advanced Chemistry System. The Chem-Elite System is a unique micro-processor controlled liquid chemistry analyser designed for high volume veterinary practices. The fully automated unit is easy to use and provides unique flexibility to the practitioner. Veterinarians can run ...

  mehr

• 16.01.2001 – 11:18

  Sechs Patente für Produkte zur Kontrolle des Flohbefalls an Heska Corporation vergeben / Das Unternehmen hält nun mehr als 100 US-Patente

  Fort Collins (ots-PRNewswire) - Die Heska Corporation (Nasdaq: HSKA), ein Marktführer auf dem Gebiet der Arzneimittel für Haustiere, gab die kürzliche Ausstellung von sechs Patenten durch das U.S. Patent and Trademark Office (US-amerikanisches Patent- und Markenamt) bekannt. Alle diese Patente beziehen sich ...

  mehr

• 03.01.2001 – 14:00

  Heska and Novartis Enter Into European Distribution Pact

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced that it has entered into a distribution agreement with Novartis Animal Health, a subsidiary of Novartis AG of Basel, Switzerland, granting Novartis exclusive distribution rights for the sale of the Heska(TM) E-Screen(TM) Test product in Europe. Financial terms of the agreement were not disclosed. (Photo: ...

  mehr

• 15.12.2000 – 19:20

  Heska Enters License Agreement With Meiji

  FORT COLLINS, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced that it has entered into a license agreement with Meiji Milk Products Co., Ltd. of Tokyo, Japan, granting Meiji non-exclusive rights to Heska's Japanese cedar pollen allergens for the manufacture and sale of human therapeutic products in Japan. Specific financial terms of the agreement, which include an up-front payment, minimum ...

  mehr

• 07.11.2000 – 18:10

  Dr. Edith W. Martin Elected to Heska Corporation's Board of Directors

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), a leader in the companion animal health market, announced today that Edith W. Martin, Ph.D. has been elected to Heska's Board of Directors. (Photo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) "We are extremely pleased with the latest addition to our board," stated Robert ...

  mehr

• 24.10.2000 – 09:41

  Heska Corporation Reports Continued Improvement in Third Quarter Financial Results

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today reported its financial results for the third quarter ended September 30, 2000. (Photo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) Total revenue decreased 3%, to $12.7 million compared to $13.1 million for the third quarter of 1999. The lower revenue in the ...

  mehr

• 23.10.2000 – 13:00

  Heska Licenses Valentis Technology for Development Of Novel Canine Cancer Treatment / Research Results Presented at Veterinary Cancer Society Meeting

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) and Valentis, Inc. (Nasdaq: VLTS) announced that Heska has licensed gene delivery and DNA manufacturing technology from Valentis. The technology will be used by Heska to complete development of a novel gene medicine for the treatment of ...

  mehr

• 12.09.2000 – 21:02

  Heska Wins Partial Summary Judgment in Synbiotics Patent Case

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced that it has received partial summary judgment in the litigation brought by Synbiotics Corporation, which claims that Heska's feline and canine heartworm diagnostic products infringe one of their patents. On September 8, 2000, the U.S. District Court for the Southern District of California granted Heska's request for partial summary ...

  mehr

• 05.09.2000 – 14:00

  Heska's ALLERCEPT(TM) Technology Proven in Clinical Allergy Studies

  Fort Collins, Colo. (ots-PRNewswire) - Scientists of Heska Corporation (Nasdaq: HSKA) presented research findings at the Fourth World Congress of Veterinary Dermatology in San Francisco, demonstrating the power of Heska(TM) ALLERCEPT(TM) technology in diagnosing veterinary allergy. Like humans, companion animals often suffer from seasonal and other allergies. Allergy is a major cause of dermatitis in dogs and cats ...

  mehr

• 28.07.2000 – 17:54

  Alliance Between Heska Corporation and Ralston Purina Results In Nutritional Product

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced that Ralston Purina Company has introduced the first nutritional product to result from the Ralston Purina-Heska alliance. CNM(R) brand DM-Formula(TM) is a revolutionary new diet available only through veterinarians for the nutritional management of feline diabetes mellitus. ...

  mehr

• 25.07.2000 – 14:00

  Heska Corporation Reports Continued Improvement in Second Quarter Financial Results

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today reported its financial results for the second quarter ended June 30, 2000. Total revenues increased 10%, to $14.2 million compared to $12.9 million for the second quarter of 1999. The growth in revenues during the second quarter of 2000 was primarily due to strong sales of vaccines ...

  mehr

• 24.07.2000 – 14:00

  Value of Heska's Allergy Patent Portfolio Further Validated by Circassia Deal

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), today announced that it has entered into a license agreement with Circassia Limited granting Circassia exclusive rights to the human therapeutic use of certain small cat allergen peptides. Heska has also granted Circassia an option to license exclusive rights to the human therapeutic use of ...

  mehr

• 05.07.2000 – 14:00

  Heska Corporation Announces Launch of New Web Site

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced that it has launched its new Web site (www.heska.com). The new site was created to expand Heska's on-line presence to include e-commerce capabilities targeted at veterinarians for instant access to Heska's broad range of companion animal health products. The newly designed Web site was created primarily for three audiences: our ...

  mehr

• 29.06.2000 – 18:18

  William A. Aylesworth Joins Heska Corporation\047s Board of Directors

  Fort Collins, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), announced today that William (Bill) A. Aylesworth has been elected to Heska's Board of Directors. Additionally, Mr. Aylesworth has been appointed as Chairman of the Audit Committee by the Board of Directors. Mr. Aylesworth is currently senior vice president and chief financial officer of ...

  mehr

• 28.06.2000 – 14:00

  Heska Corporation Obtains Expanded Credit Facility

  FORT COLLINS, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced that it has entered into an expanded $13.1 million, two-year credit facility with Wells Fargo Business Credit, an affiliate of Wells Fargo Bank. The expanded credit facility has two components: First, two existing term loans totaling approximately $3.1 million at Heska's Diamond Animal Health subsidiary in Des Moines, Iowa have ...

  mehr

• 26.06.2000 – 14:00

  Heska Corporation Announces Sale of Center Laboratories Business to Alk-Abello / Deal Also Includes Intellectual Property License For Human Healthcare Applications

  FORT COLLINS, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced the sale of its Center Laboratories business to Alk-Abello ("ALK"), a part of the Chr. Hansen Group, based in Denmark. Center Laboratories manufactures and sells allergen extracts and immunotherapy treatment sets used in the ...

  mehr

• 13.06.2000 – 08:57

  Heska Corporation Announces Launch of New Feline Diagnostic Product

  FORT COLLINS, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA), a leader in the companion animal health market, today announced the introduction of the HESKA(R) Feline ImmuCheck(TM) Assays in its Veterinary Diagnostic Laboratories. This innovative diagnostic product is used to determine the serum levels of antibodies that are specific to three common viral diseases of cats: feline panleukopenia virus (FPV), ...

  mehr

• 31.05.2000 – 12:00

  Heska Appoints New Board Chairman

  FORT COLLINS, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced that in conjunction with its Annual Meeting of Shareholders, the Board of Directors appointed Robert B. Grieve as Chairman of the Board. Dr. Grieve, a founder of the Company, has served as Chief Executive Officer since January 1, 1999 and will continue in that capacity. Heska discovers, develops, manufactures and markets companion animal health products, primarily for dogs, cats ...

  mehr

• 25.04.2000 – 13:00

  Heska Corporation Reports Record Revenues in First Quarter Results / Company Delivers Strong Revenue Growth, Higher Margins and Improved Operating Results

  FORT COLLINS, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today reported its financial results for the first quarter ended March 31, 2000. Total revenues increased 30% to $14.4 million for the quarter compared to $11.1 million for the first quarter of 1999. This represents the highest quarterly ...

  mehr

• 04.04.2000 – 14:00

  Heska Corporation Announces Sale of Dental Product to Pharmacia & Upjohn

  FORT COLLINS, Colo. (ots-PRNewswire) - Heska Corporation (Nasdaq: HSKA) today announced that it has sold the worldwide rights to its PERIOceutic(TM) Gel product for the treatment of periodontal disease in dogs to Pharmacia & Upjohn Animal Health. Under the terms of the agreement, Pharmacia & Upjohn will begin marketing the product after a transition period. In ...

  mehr